Home › Compare › QBBHY vs ABBV
QBBHY yields 2.59% · ABBV yields 3.06%● Live data
📍 QBBHY pulled ahead of the other in Year 4
Combined, QBBHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QBBHY + ABBV for your $10,000?
Qube Holdings Limited, together with its subsidiaries, provides logistics solutions for import and export supply chain in Australia, New Zealand, and internationally. The company's Operating division offers services relating to the import and export of primarily containerized cargo; provides various logistics services, which includes road and rail transport, warehousing and distribution, container parks, and related services, as well as operates intermodal logistics hubs, including rail terminals and international freight forwarding; owns and operates automotive terminals that provides automotive, general cargo, and break-bulk facilities; operates multi-user grain storage and handling facilities; and develops and operates an import-export rail terminal, and an interstate rail terminal at the Moorebank Logistics Park. This division also provides bulk and general handling facilities; and bulk material handling services, including road and rail transport, stockpile management, and bulk ship loading services. Its Patrick Terminals division provides container stevedoring services in Australia. The company was formerly known as Qube Logistics Holdings Limited and changed its name to Qube Holdings Limited in November 2012. Qube Holdings Limited was incorporated in 2011 and is based in Sydney, Australia.
Full QBBHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.